Earnings summaries and quarterly performance for VERU.
Executive leadership at VERU.
Board of directors at VERU.
Research analysts who have asked questions during VERU earnings calls.
WW
William Wood
B. Riley Securities
6 questions for VERU
Also covers: ALT, GUTS, IMUX +3 more
Gary Nachman
Raymond James
3 questions for VERU
Also covers: ABBV, ACHV, ADMA +9 more
LG
Leland Gershell
Oppenheimer & Co. Inc.
3 questions for VERU
Also covers: ARGX, ASND, CAPR +13 more
AL
Anthea Li
Jefferies
2 questions for VERU
Also covers: CRNX, ROIV
Rohan Mathur
Oppenheimer & Co. Inc.
2 questions for VERU
Also covers: CPRX, CRNX, CYTK
Denis Reznik
Raymond James
1 question for VERU
Also covers: AQST, INMB, PCRX
DD
Dennis Ding
Jefferies Financial Group Inc.
1 question for VERU
Also covers: ARDX, CARA, FOLD +5 more
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
1 question for VERU
Also covers: ANGO, BLFS, CDXC +8 more
Robert Sassoon
Water Tower Research LLC
1 question for VERU
Also covers: VVOS, YI, ZOM
YC
Yi Chen
H.C. Wainwright & Co.
1 question for VERU
Also covers: ANGO, APDN, BLFS +22 more
Recent press releases and 8-K filings for VERU.
Veru Reports Fiscal Year 2025 Results, Sells FC2 Business, and Advances Enobosarm Clinical Program
VERU
Earnings
M&A
New Projects/Investments
- Veru reported a net loss from continuing operations of $15.7 million, or $1.07 per diluted common share, for the fiscal year ended September 30, 2025, an improvement from the prior year. Research and development costs increased to $15.6 million in fiscal 2025, driven by the Phase 2b obesity clinical study for enobosarm.
- The company completed the sale of its FC2 Female Condom business on December 30, 2024, for $18 million in cash, yielding approximately $16.5 million in net proceeds and resulting in a $4.1 million loss on sale. This strategic divestiture allows Veru to focus exclusively on drug development.
- Subsequent to the fiscal year-end, on October 31, 2025, Veru completed an underwritten public offering, raising approximately $23.4 million in net proceeds. As of September 30, 2025, cash, cash equivalents, and restricted cash totaled $15.8 million.
- Veru announced positive Phase 2b QUALITY clinical trial results for enobosarm, demonstrating 100% average preservation of total lean mass and 12% greater fat loss at 16 weeks when combined with semaglutide. The company plans to initiate the Phase 2b PLATEAU clinical trial to further evaluate enobosarm in older patients with obesity (BMI ≥35, age ≥65) who are initiating GLP-1 receptor treatment.
Dec 17, 2025, 1:00 PM
Veru Inc. Reports Q4 2025 Financials, Sells FC2 Business, and Advances Enobosarm Clinical Program
VERU
Earnings
New Projects/Investments
M&A
- Veru completed the sale of its FC2 female condom business on December 30, 2024, for $18 million in cash, shifting its focus exclusively to drug development.
- For fiscal year 2025, the company reported a net loss from continuing operations of $15.7 million (or $1.07 per diluted common share) and a net loss from discontinued operations of $7 million (or $0.48 per diluted common share).
- As of September 30, 2025, cash, cash equivalents, and restricted cash totaled $15.8 million, supplemented by $23.4 million in net proceeds from a public offering completed on October 31, 2025.
- The company announced positive Phase 2b QUALIFY clinical trial results for Enobosarm, showing 100% average preservation of total lean mass and 12% greater fat loss at 16 weeks when combined with semaglutide.
- Veru plans to initiate the Phase 2b PLATEAU clinical trial for Enobosarm in Q1 2026, targeting older patients with obesity and a BMI greater than or equal to 35, with an interim analysis expected in Q1 2027. The current cash position is sufficient to fund operations through this interim analysis.
Dec 17, 2025, 1:00 PM
Veru Reports Q4 2025 Results, Sells FC2 Business, and Advances Enobosarm Program
VERU
Earnings
M&A
New Projects/Investments
- Veru Inc. reported a net loss from continuing operations of $15.7 million, or $1.07 per diluted common share, for fiscal year 2025.
- The company sold its FC2 female condom business on December 30, 2024, for $18 million in cash, with $16.5 million in net proceeds, as part of a strategic shift to focus exclusively on drug development.
- A public offering completed on October 31, 2025, generated approximately $23.4 million in net proceeds.
- Veru announced positive Phase 2b QUALIFY clinical trial results for Enobosarm, demonstrating 100% average preservation of total lean mass and 12% greater fat loss at 16 weeks when combined with semaglutide.
- The company plans a Phase 2b PLATEAU clinical trial for Enobosarm, targeting older patients with obesity, and its current cash is sufficient to fund operations through the interim analysis of this study.
Dec 17, 2025, 1:00 PM
Veru Reports Fiscal Year 2025 Financial Results and Enobosarm Clinical Program Progress
VERU
Earnings
Guidance Update
New Projects/Investments
- Veru Inc. reported a net loss of $22.7 million, or $1.55 per share, for fiscal year 2025, and an operating loss from continuing operations of $24.8 million.
- The company announced positive efficacy and safety results from its Phase 2b QUALITY study for enobosarm, demonstrating 100% average preservation of total lean mass and 12% greater fat loss at 16 weeks when combined with semaglutide.
- The FDA has provided regulatory clarity, accepting incremental weight loss as an approvable primary endpoint for enobosarm in combination with GLP-1 RA, and confirmed enobosarm 3 mg as an acceptable dosage for future clinical development.
- Veru plans to initiate the Phase 2 PLATEAU clinical study in calendar Q1 2026, with interim analysis results anticipated in Q1 calendar year 2027.
- As of September 30, 2025, cash, cash equivalents, and restricted cash totaled $15.8 million, with an additional $23.4 million in net proceeds from a public offering completed post fiscal year-end.
Dec 17, 2025, 12:00 PM
Veru Inc. Prices Public Offering of Common Stock and Warrants
VERU
New Projects/Investments
- Veru Inc. announced the pricing of a public offering including 1,400,000 shares of common stock, pre-funded warrants to purchase up to 7,000,000 shares, and accompanying Series A and Series B warrants, each to purchase up to 8,400,000 shares of common stock.
- The combined public offering price for each share of common stock with accompanying warrants is $3.00, and for each pre-funded warrant with accompanying warrants is $2.999.
- The offering is expected to generate approximately $25.2 million in gross proceeds, with potential additional gross proceeds of approximately $50.4 million if all warrants are exercised in cash.
- Net proceeds from the offering will primarily fund the development of enobosarm, focusing on Phase 2b PLATEAU clinical study activities, as well as working capital and general corporate purposes.
- The Series A warrants have an exercise price of $3.00 and terminate on October 31, 2030. The Series B warrants also have an exercise price of $3.00 and terminate on the earlier of October 31, 2028, or 45 days after a specific milestone event related to enobosarm clinical data and stock price performance.
Oct 30, 2025, 8:15 PM
Veru Prices Public Offering
VERU
New Projects/Investments
- Veru Inc. priced an underwritten public offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants, with an expected closing date of October 31, 2025.
- The offering is anticipated to generate approximately $25.2 million in gross proceeds for Veru, with potential for an additional $50.4 million if all warrants are exercised.
- Net proceeds will be primarily allocated to fund the development of enobosarm, specifically for Phase 2b PLATEAU clinical study activities, and for general corporate purposes.
Oct 30, 2025, 12:00 PM
Veru Announces Proposed Public Offering
VERU
- Veru Inc. has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock) and accompanying Series A and Series B warrants to purchase shares of its common stock.
- The net proceeds from the proposed offering are intended to fund the development of enobosarm, with a primary focus on Phase 2b PLATEAU clinical study activities, as well as for working capital and other general corporate purposes.
- Canaccord Genuity LLC and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.
Oct 29, 2025, 8:01 PM
Veru Reports Positive Phase 2b Enobosarm Results and Outlines Future Development Plans
VERU
New Projects/Investments
Product Launch
M&A
- Veru announced positive Phase 2b results for its drug Enobosarm, which, when combined with GLP-1 receptor agonists, demonstrated a 71% relative reduction in lean mass loss and a 46% relative greater loss of fat (with the 6mg dose) compared to GLP-1 alone. The 3mg dose resulted in 99.1% of weight loss being fat.
- The study also showed a 54.4% reduction in patients experiencing a greater than 10% decline in stair climb power, indicating a significant functional benefit in older patients. An independent data monitoring committee recommended continuing the study as planned as of February 10, 2025.
- Veru is preparing for a Phase 3 meeting with the FDA and developing a novel oral modified release Enobosarm formulation, with a Phase 1 bioavailability trial expected in H1 2025. Top-line results for a separate maintenance study are anticipated in Q2 2025.
- The company reported $25 million in cash as of September 30, 2024, and has no debt after selling its FC2 business for a net of $12.5 million and extinguishing $9.9 million of debt. Veru also highlighted strong intellectual property protection for Enobosarm, with patents extending to 2044.
Feb 11, 2025, 5:00 PM
Quarterly earnings call transcripts for VERU.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more